KHIRON LIFE SCIENCES CORP - KHRNF STOCK NEWS

Khiron Life Sciences has opened its 4th Zerenia-branded medical cannabis clinic in Bogota, Colombia. The new 4,000 sq.ft. facility can handle up to 40,000 consultations annually, potentially increasing patient capacity by 20%. Strategically located in Plaza Central, a busy shopping center near leading insurance companies, this expansion continues Khiron's growth strategy. In 2021, the company saw over 900% growth in medical cannabis sales in Colombia. Khiron also engaged Arrowhead for investor relations, with an initial six-month contract worth USD$50,000.

Khiron Life Sciences Corp. announces that as of January 1, 2022, all insurance providers in Colombia must cover high and low THC medical cannabis prescriptions. This change simplifies the insurance approval process for patients and taps into a potential market of over 6 million patients, with more than 97% already insured. In 2021, Khiron filled nearly 52,000 medical cannabis prescriptions, nine times more than in 2020. The company's sales growth is supported by mandatory coverage, enhancing its position in the Colombian medical cannabis market.

Khiron Life Sciences Corp. (TSXV: KHRN; OTCQX: KHRNF) announced CEO Alvaro Torres will participate in the Lytham Partners Winter 2021 Investor Conference from December 13-16, 2021. The event includes a webcasted Fireside Chat scheduled for 11:00 am ET on December 13, discussing Khiron's 2022 vision. Recent highlights include opening a clinic in London, achieving $3.5 million in Q3 2021 revenue (83% YoY increase), and filling over 50,000 medical cannabis prescriptions in Latin America. More details are available on the company's website.

Khiron Life Sciences Corp. (KHRNF) announced the granting of 1,400,000 stock options and 950,000 restricted share units (RSUs) to its officers. These grants are subject to performance-based vesting conditions. The stock options have an exercise price of $0.75 per share and expire on November 23, 2026, while unvested RSUs will expire on December 15, 2024. This announcement follows shareholder approval of an amended restricted share unit plan. Khiron operates in Latin America and Europe, focusing on medical cannabis and leveraging telemedicine platforms.

Khiron Life Sciences Corp. reported a strong Q3 2021, with revenues increasing by 83% year-over-year to $3.5 million. The medical cannabis segment contributed $1.2 million, marking a 46% sequential growth. Gross profit before fair value adjustments rose by 62% sequentially, reaching $1.7 million. The company's gross margins in this sector stood at 89%. Additionally, net loss decreased to $3.3 million from $6.7 million in Q3 2020, signaling improved financial health.

Khiron Life Sciences Corp. (TSXV: KHRN, OTCQX: KHRNF) will host a conference call on November 22, 2021, at 10:00 a.m. Eastern Time to discuss its third quarter financial results for the period ending September 30, 2021. Interested individuals, including investors and analysts, are invited to participate in the call, which will include a Q&A session. Financial results will be released prior to the call. A telephonic replay will be available from 8:00 p.m. Eastern Time on the same day through November 29, 2021.

Khiron Life Sciences Corp. (TSXV: KHRN, OTCQX: KHRNF) will participate in several investor conferences throughout November 2021. Key events include the Cannabis Europa in London on November 10-11, the Q4 Virtual Investor Summit on November 16, and the Cowen's 4th Annual Cannabis Virtual Conference from November 29 to December 1. The company aims to leverage these opportunities to enhance investor relations and showcase its vertical integration in the cannabis industry across Latin America and Europe.

Khiron Life Sciences has launched Zerenia™ Clinics UK in London, marking its first European clinic. This expands Khiron's global clinic count to 15, enhancing access to medical cannabis for UK patients. The hybrid model combines digital and in-person consultations, focusing initially on pain management. Khiron's European sales account for 30% of its total revenue, with significant growth anticipated in the UK market. Established in 2019, the company aims to improve medical cannabis access and training for healthcare professionals.

Khiron Life Sciences has presented results from its first observational study at the International Pain Conference in Colombia on September 25, 2021. This study involved 1,453 patients treated at Khiron's Zerenia clinics using CBD and THC oils. The findings revealed over 80% of participants reported positive outcomes for conditions like chronic pain and anxiety. The study is the first of its kind in Latin America, focusing on patient-reported outcomes and satisfaction. The research supports Khiron's ongoing commitment to establishing the efficacy of medical cannabis.